New Clinical Data On Evaxion's AI-Immunology-Based Personalized Cancer Vaccines To Be Presented
Portfolio Pulse from Benzinga Newsdesk
Evaxion Biotech A/S (NASDAQ:EVAX) will present clinical data from two personalized cancer vaccine trials at the Society for Immunotherapy of Cancer's annual meeting. The data will further strengthen Evaxion's position as a pioneering cancer vaccine company. The trials involve the AI-designed personalized neoantigen vaccine, EVX-02, and the AI-generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab.
October 26, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evaxion's presentation of positive clinical data from its cancer vaccine trials could boost investor confidence and potentially impact its stock positively in the short term.
The presentation of positive clinical data from Evaxion's cancer vaccine trials at a prestigious conference could increase investor confidence in the company's capabilities and potential, possibly leading to a short-term increase in its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100